Ziccum AB (publ) has signed an Evaluation Agreement with ReCode Therapeutics Inc. (ReCode), a US clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, for evaluation of LaminarPace enabling dry powder forms of ReCode's proprietary therapeutic modalities. Ziccum AB signed an Evaluation agreement with ReCode on June 19th, 2024. The study will focus on evaluating Ziccum's formulation and drying technology LaminarPace to enable dry powder forms of ReCode material: therapeutic messenger-RNA in specific liquid lipid nanoparticle formulation, mRNA /LNP, on ReCode's proprietary SORT platform.

The LaminarPace performance will be evaluated by analytical assessment of the resulting mRNA /LNP dry product, with technical parameters as well as mRNA activity in cell transfection.